Evidence map›Paper›PMID 26366338›Full record

ArticleCurrent pharmacology reports2015

Regulation of miRNAs by agents targeting the tumor stem cell markers DCLK1, MSI1, LGR5, and BMI1.

Sripathi M Sureban, Dongfeng Qu, Courtney W Houchen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current pharmacology reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12.Journal of experimental & clinical cancer research : CR · 2019
    Article
  4. Article
  5. Review
  6. Review
  7. Expression Patterns forAvicenna journal of medical biotechnology
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sripathi M SurebanDepartment of Internal Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK 73104 ; Department of Veterans Affairs Medical Center, Oklahoma City, OK 73104 ; Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, OK 73104 Phone number: (405) 271-2175/fax number: (405) 271-5450.
Dongfeng QuDepartment of Internal Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK 73104 ; Department of Veterans Affairs Medical Center, Oklahoma City, OK 73104 ; Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, OK 73104 Phone number: (405) 271-2175/fax number: (405) 271-5450.
Courtney W HouchenDepartment of Internal Medicine, University of Oklahoma Health Science Center, Oklahoma City, OK 73104 ; Department of Veterans Affairs Medical Center, Oklahoma City, OK 73104 ; Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, OK 73104 Phone number: (405) 271-2175/fax number: (405) 271-5450.
University of Oklahoma Health Sciences Center · US

Funding

Targeting DCLK1 kinase activity in pancreatic cancerR21CA186175 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HOUCHEN, COURTNEY WAYNE · 2015 to 2016
$354k
Pancreatic Stem Cells and CancerR21CA137482 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI HOUCHEN, COURTNEY WAYNE · 2010 to 2011
$346k
NCI NIH HHS R21 CA137482NCI NIH HHS R21 CA186175
6 · The paper itself

Abstract

Gastrointestinal cancers such as colorectal, pancreatic, liver, gastric, and esophageal, are the most common forms of malignant cancers. MicroRNAs (miRNA) play important role in regulating gastrointestinal cancer progress either as potent oncogenes or tumor suppressors. In this report, we will discuss the importance of several tumor suppressors involved in colon or pancreatic cancer. Some recent studies on tumor stem cells and regulation of these miRNAs via agents targeting the tumor stem cell markers doublecortin-like kinase 1 (DCLK1), Musashi-1 (MSI1), polycomb protein BMI1, and WNT genes (LGR5 and ASCL2) will also be discussed. Agents such as siRNA/shRNA, small molecule kinase inhibitors, and general herbal drugs (curcumin) targeting these tumor stem cell markers and tumor suppressor miRNAs could be the perfect therapeutic agents for the treatment of these cancers.

Indexed as

BMI1DCLK1LGR5MSI1Tumor stem cell markersTumor suppressor miRNAs

Identifiers

PMID26366338
PMCPMC4562791
OpenAlexW2001849545

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.